However, as with any vaccine aiming to induce CD8+ T cells, this does not really translate into certainty in obtaining high or tumor protective CD8+ T cell responses in humans, as, at best, tumor protection studies in animals, even transgenic animals, can only be indicative of vaccine potential. The gene discussed is CD8A; the disease is neoplasm.